Cancer Treatment Centers of America® at Midwestern Regional Medical Center, Zion, IL 60099, USA.
BMC Cancer. 2011 Aug 15;11:353. doi: 10.1186/1471-2407-11-353.
There are conflicting and inconsistent results in the literature on the prognostic role of quality of life (QoL) in cancer. We investigated whether QoL at admission could predict survival in lung cancer patients.
The study population consisted of 1194 non-small cell lung cancer patients treated at our institution between Jan 2001 and Dec 2008. QoL was evaluated using EORTC-QLQ-C30 prior to initiation of treatment. Patient survival was defined as the time interval between the date of first patient visit and the date of death from any cause/date of last contact. Univariate and multivariate Cox regression evaluated the prognostic significance of QoL.
Mean age at presentation was 58.3 years. There were 605 newly diagnosed and 589 previously treated patients; 601 males and 593 females. Stage of disease at diagnosis was I, 100; II, 63; III, 348; IV, 656; and 27 indeterminate. Upon multivariate analyses, global QoL as well as physical function predicted patient survival in the entire study population. Every 10-point increase in physical function was associated with a 10% increase in survival (95% CI = 6% to 14%, p < 0.001). Similarly, every 10-point increase in global QoL was associated with a 9% increase in survival (95% CI = 6% to 11%, p < 0.001). Furthermore, physical function, nausea/vomiting, insomnia, and diarrhea (p < 0.05 for all) in newly diagnosed patients, but only physical function (p < 0.001) in previously treated patients were predictive of survival.
Baseline global QoL and physical function provide useful prognostic information in non-small cell lung cancer patients.
文献中关于生活质量(QoL)对癌症预后作用的结果存在矛盾和不一致。我们研究了入院时的 QoL 是否可以预测肺癌患者的生存。
研究人群包括 2001 年 1 月至 2008 年 12 月在我们机构治疗的 1194 名非小细胞肺癌患者。在开始治疗前使用 EORTC-QLQ-C30 评估 QoL。患者生存定义为首次就诊日期与任何原因导致的死亡日期/最后联系日期之间的时间间隔。单变量和多变量 Cox 回归评估了 QoL 的预后意义。
就诊时的平均年龄为 58.3 岁。新诊断患者 605 例,既往治疗患者 589 例;男性 601 例,女性 593 例。诊断时的疾病分期为 I 期 100 例,II 期 63 例,III 期 348 例,IV 期 656 例,27 例无法确定。多变量分析显示,全球 QoL 以及身体功能在整个研究人群中预测了患者的生存。身体功能每增加 10 分,生存率就会增加 10%(95%CI=6%至 14%,p<0.001)。同样,全球 QoL 每增加 10 分,生存率就会增加 9%(95%CI=6%至 11%,p<0.001)。此外,新诊断患者的身体功能、恶心/呕吐、失眠和腹泻(p<0.05 所有),但仅在既往治疗患者中,身体功能(p<0.001)与生存相关。
基线全球 QoL 和身体功能为非小细胞肺癌患者提供了有用的预后信息。